Lantheus doses first patient in SPARROW Phase 2/3 prostate cancer imaging trial for LNTH-2401

By Public Technologies
  • Lantheus dosed the first patient in SPARROW, a Phase 2/3 registrational study of LNTH-2401 PET imaging in prostate cancer.
  • No clinical results were presented; the trial is designed to generate data for a future diagnostic performance readout.
  • The study aims to show LNTH-2401 can help detect and characterize prostate cancer using a GRPR-targeted approach complementary to PSMA imaging.
  • Phase 3 is expected to enroll about 400 participants, positioning the program as a potential pipeline expansion in prostate cancer imaging.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834386) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.